MOUSE/HUMAN CHIMERIC ANTI-PHENCYCLIDINE ANTIBODY AND USES THEREOF

• US 20070207145A1
• Filed: 04/23/2007
• Published: 09/06/2007
• Est. Priority Date: 04/21/2003
• Status: Abandoned Application

• Current Assignee: The Board of Trustees of the University of Arkansas (University of Arkansas System)
• Original Assignee: The Board of Trustees of the University of Arkansas (University of Arkansas System)
• Inventors: Owens, S. Michael, Lacy, H. Marie
• Application Number:
  US11/738,789
• Publication Number:
  US 20070207145A1
• Time in Patent Office: Days
• US Class Current: 424/133.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The present invention provides a chimeric mouse/human antibody (ch-mAb6B5) for treatment of abuse and toxicity of the arylcyclohexylamines class of drugs (i.e., phencyclidine- or PCP-like drugs). This antibody comprises light and heavy chain PCP binding regions of mouse mAb6B5, coupled to the light and heavy chain constant regions of a human kappa IgG₂ or IgG₄ isoform. Also provided are the DNA and amino acid sequences of the chimeric light and heavy chain of this antibody. Further provided are data that demonstrate that the new chimeric antibody retains the high affinity and specificity of a previously generated mouse anti-PCP monoclonal antibody (mAb6B5) yet being minimally immunogenic since it has human immunoglobulin constant region. This new medication would allow safe and effective treatment of PCP drug overdose, decrease mortality, and reduce harmful effects due to excessive and prolonged PCP drug use.

Claims

1. A method of treating arylcyclohexylamine drug abuse, the method comprising administering a chimeric mouse/human monoclonal antibody specific for phencyclidine or phencyclidine-like drugs to a subject, wherein administration of the chimeric antibody modulates the adverse effects of arylcyclohexylamine drug abuse.

2. The method of claim 1, wherein the arylcyclohexylamine is selected from the group consisting of phencyclidine (PCP), 1-[1-(2-thienyl)cyclohexyl] piperidine (TCP), and N-ethyl-1-phenylcyclohexylamine (PCE) or other structurally similar, psychoactive analogs thereof.

3. The method of claim 1, wherein the mouse/human chimeric antibody comprises the variable regions of mAb6B5.

4. The method of claim 1, wherein the subject is selected from the group consisting of a rodent, a non-human primate, and a human.

5. The method of claim 4, wherein the subject is using phencyclidine.

6. The method of claim 4, wherein the subject overdosed on phencyclidine.

7. The method of claim 1, wherein the chimeric antibody decreases the concentration of phencyclidine (PCP), 1-[1-(2-thienyl)cyclohexyl] piperidine (TCP), or N-ethyl-1-phenylcyclohexylamine (PCE) in the brain of the subject.

8. The method of claim 1, wherein the pharmaceutically effective amount is about 5 mg to about 45 mg of chimeric antibody per kilogram of subject body weight.

9. A method of treating phencyclidine drug abuse, the method comprising administering a pharmaceutically effective amount of a chimeric mouse/human monoclonal antibody specific for phencyclidine to a subject, wherein administration of the chimeric antibody modulates the adverse effects of phencyclidine drug abuse.

10. The method of claim 9, wherein the mouse/human chimeric antibody comprises the variable regions of mAb6B5.

11. The method of claim 9, wherein the subject is selected from the group consisting of a rodent, a non-human primate, and a human.

12. The method of claim 11, wherein the subject is using phencyclidine.

13. The method of claim 11, wherein the subject overdosed on phencyclidine.

14. The method of claim 9, wherein the chimeric antibody decreases the concentration of phencyclidine in the brain of the subject.

15. The method of claim 9, wherein the pharmaceutically effective amount is about 5 mg to about 45 mg of chimeric antibody per kilogram of subject body weight.

16. A method of decreasing the concentration of phencyclidine in the brain of a subject, the method comprising administering a pharmaceutically effective amount of a chimeric mouse/human monoclonal antibody specific for phencyclidine to the subject.

17. The method of claim 16, wherein the subject is selected from the group consisting of a rodent, a non-human primate, and a human.

18. The method of claim 17, wherein the subject is using phencyclidine or overdosed on phencyclidine.

19. The method of claim 16, wherein the mouse/human chimeric antibody comprises the variable regions of mAb6B5.

20. The method of claim 16, wherein the pharmaceutically effective amount is about 5 mg to about 45 mg of chimeric antibody per kilogram of subject body weight.